colchicine - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 0.83 [0.35, 1.95]< 10%1 study (1/-)66.5 %NAnot evaluable crucial-
deaths 0.74 [0.24, 2.31]< 10%3 studies (3/-)69.9 %NAnot evaluable crucial-
hospital discharge 1.13 [0.76, 1.67]> 10%1 study (1/-)73.0 %NAnot evaluable important-
ICU admission 1.06 [0.06, 18.45]< 10%1 study (1/-)48.4 %NAnot evaluable non important-

safety endpoints 00

adverse events 1.63 [0.67, 3.95]< 10%1 study (1/-)14.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.